Hantz Financial Services Inc. Buys 35,294 Shares of Enovis Co. (NYSE:ENOV)

Hantz Financial Services Inc. lifted its stake in shares of Enovis Co. (NYSE:ENOV) by 18.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,396 shares of the company’s stock after purchasing an additional 35,294 shares during the quarter. Hantz Financial Services Inc.’s holdings in Enovis were worth $9,660,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ENOV. FORA Capital LLC bought a new position in shares of Enovis in the 3rd quarter worth $650,000. MetLife Investment Management LLC lifted its stake in shares of Enovis by 9.4% in the third quarter. MetLife Investment Management LLC now owns 28,839 shares of the company’s stock valued at $1,242,000 after buying an additional 2,476 shares in the last quarter. Bridgewater Associates LP grew its holdings in shares of Enovis by 80.1% during the third quarter. Bridgewater Associates LP now owns 17,588 shares of the company’s stock valued at $757,000 after buying an additional 7,823 shares during the last quarter. FMR LLC grew its holdings in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after buying an additional 484 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP increased its position in shares of Enovis by 49.5% during the third quarter. Advantage Alpha Capital Partners LP now owns 87,955 shares of the company’s stock worth $3,786,000 after acquiring an additional 29,139 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Up 0.7 %

Shares of NYSE:ENOV opened at $48.81 on Friday. The company has a market capitalization of $2.73 billion, a PE ratio of -22.29 and a beta of 1.91. Enovis Co. has a 1 year low of $38.27 and a 1 year high of $65.03. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a fifty day moving average price of $43.18 and a two-hundred day moving average price of $44.91.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same quarter last year, the company posted $0.56 earnings per share. The firm’s quarterly revenue was up 21.0% compared to the same quarter last year. Analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th. JPMorgan Chase & Co. cut their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. JMP Securities began coverage on Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price target for the company. Finally, Evercore ISI cut their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.